Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;24(2):350-362.
doi: 10.1007/s12094-021-02696-5. Epub 2021 Oct 29.

Future care for long-term cancer survivors: towards a new model

M Provencio  1 , N Romero  2 , J Tabernero  3 , R Vera  4 , D V Baz  5 , A Arraiza  6 , C Camps  7 , E Felip  8 , P Garrido  9 , B Gaspar  10 , M Llombart  11 , A López  12 , I Magallón  13 , V M Ibáñez  14 , J M Olmos  15 , C Mur  16 , A Navarro-Ruiz  17 , A Pastor  18 , M Peiró  19 , J Polo  20 , Á Rodríguez-Lescure  21
Affiliations

Future care for long-term cancer survivors: towards a new model

M Provencio et al. Clin Transl Oncol. 2022 Feb.

Abstract

Purpose: The increase in the prevalence "long-term cancer survivor" (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care.

Methods: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report.

Results: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions.

Conclusion: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.

Keywords: LCS patient care; Long cancer survivor; Multidisciplinary cancer care.

PubMed Disclaimer

Conflict of interest statement

M Provencio reports grants, personal fees and non-financial support from BMS, grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Astrazeneca, personal fees from MSD, personal fees from Takeda, outside the submitted work. J Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech, Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc. He declares institutional financial interest in form of financial support for clinical trials or contracted research for Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, Janssen-Cilag SA, Merck Sharp & Dohme, Novartis Farmacéutica SA, Taiho Pharma USA Inc, Pharma Mar, Spanish Association Against Cancer Scientific Foundation and Cancer Research UK. R Vera declares that she has no conflict of interest. A Arraiza declares that he has no conflict of interest. E Felip reports personal fees for speaking or attending advisory boards for: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Novartis, Peptomyc, Peervoice, Pfizer, Regeneron, Sanofi, Syneos Health, Seattle Genetics, Takeda, Touch Medical. She is an independent member of the board at GRÍFOLS. P Garrido declare personal financial interests: Abbvie, Advisory Role, Amgen, Advisory Role, AstraZeneca, Speaker, Advisory Role, Bayer, Advisory Role, Boehringer Ingelheim, Speaker, Advisory Role, Bristol (BMS), Speaker, Advisory Role, GlaxoSmithKline (GSK), Advisory Role, Janssen, Speaker, Advisory role, Lilly, Advisory Role, MSD, Speaker, Advisory Role, Novartis, Speaker, Advisory Role, Pfizer, Speaker, Advisory Role, Roche, Speaker, Advisory Role, Takeda, Advisory Role, Speaker, Spouse: BI, Speaker, Advisory Role, Gebro, Advisory Role, Janssen, Speaker, Advisory Role, Nordic, Advisory Role, Steering Committee: Janssen. A López declares that he has refused funding for this project. C Mur declares that he has no conflict of interest. A Navarro declares he has received fee for AstraZeneca. A Pastor declares that she has no conflict of interest. M Peiró declares that Astra Zeneca has made payments to ESADE, on behalf of the Institute for Healthcare Management, for the strategic direction of the ASISTO project. J Polo states that in the last 3 years he has received honoraria for presentations at national congresses in activities sponsored by Boehringer Ingelheim, Bayer, Daiichi-Sankyo. Pfizer—BMS, Menarini. Almirall Bial. Honoraria as author of multiple publications sponsored by Boehringer Ingelheim, Bayer, Pfizer—BMS, Novartis, Bial, Almirall. Fees as scientific committee of studies: Degree of control of ACO in Spain PAULA Study (funded by Bayer) ESCONDIDA Study (Pfizer—BMS) and SAMOA Study (Pfizer—BMS) Study of quality control of ACO in Spain funded by Boehringer Ingelheim. GLORIA AF study funded by Boehringer Ingelheim, PREFER study funded by Novartis, AGORA study funded by MSD. A Rodríguez-Lescure. COIs: Employment: None. Consultant or Advisory Role: Roche, Pfizer, Novartis, Lilly, MSD, AstraZeneca, Daiichi-Sankyo. Stock Ownership: None. Research Funding: To my Institution: Roche, Novartis, Pfizer, Lilly, AstraZeneca, Amgen, MSD, BMS, Zymeworks, GEICAM. o my person: None. Speaking: Roche, Pfizer, Novartis, Lilly, A-Z, MSD, Merck, Pierre- Fabré, Ipsen. Grant support: None Other: Travel, Accommodations (ASCO, SABCS): Roche, Pfizer.

Figures

Fig. 1
Fig. 1
Level of agreement reached for each section in the Delphi study
See this image and copyright information in PMC

References

    1. Derksen JWG, Beijer S, Koopman M, Verkooijen HM, van de Poll-Franse LV, May AM. Monitoring potentially modifiable lifestyle factors in cancer survivors: a narrative review on currently available methodologies and innovations for large-scale surveillance. Eur J Cancer. 2018;103:327–340. doi: 10.1016/j.ejca.2018.06.017. - DOI - PubMed
    1. Lagergren P, Schandl A, Aaronson NK, Adami HO, de Lorenzo F, Denis L, et al. Cancer survivorship: an integral part of Europe's research agenda. Mol Oncol. 2019;13:624–635. doi: 10.1002/1878-0261.12428. - DOI - PMC - PubMed
    1. Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou-Zeid N, et al. Towards a cancer mission in Horizon Europe: recommendations. Mol Oncol. 2020;14(8):1589–1615. doi: 10.1002/1878-0261.12763. - DOI - PMC - PubMed
    1. Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017;18:e19–e29. doi: 10.1016/S1470-2045(16)30386-2. - DOI - PubMed
    1. Ferro T, Borras JM. The growing snowball in health services: long-term cancer survivors. Gac Sanit. 2011;25:240–245. doi: 10.1016/j.gaceta.2010.12.002. - DOI - PubMed

Publication types